[Systemic treatment of non-small cell lung cancer--recommendations based on the results of reliable clinical trials].
Lung cancer is in Poland the most common malignancy. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung tumors. In the multidisciplinary treatment of non-small cell lung cancer patients the role of chemotherapy and, most recently, molecular targeted therapy is increasing. In 2005 we published recommendations for systemic treatment of non-small cell lung cancer and mesothelioma. As many new studies have been published since, it was necessary to update this document. We present here a consensus statement on this topic, prepared by a panel of experts in oncology, thoracic surgery, pathology and pneumonology.
Jassem
Jacek
J
Katedra i Klinika Onkologii i Radioterapii, Akademia Medyczna w Gdańsku, Gdańsk. jjassem@amg.gda.pl
Drosik
Kazimierz
K
Dziadziuszko
Rafał
R
Kordek
Radzisław
R
Kozielski
Jerzy
J
Kowalski
Dariusz
D
Krzakowski
Maciej
M
Nikliński
Jacek
J
Olszewski
Włodzimierz
W
Orłowski
Tadeusz
T
Ramlau
Rodryg
R
Roszkowski-Sliz
Kazimierz
K
D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D003245:Consensus Statements as Topic; D006801:Humans; D008654:Mesothelioma / Q000628:therapy*; D010997:Pleural Neoplasms / Q000628:therapy*; D011044:Poland